YaoGeJu

Company directoryChina company filings

Yangzhou Aurisco Pharmaceutical Co.,Ltd.

As of 18 November 2026, for the company name Yangzhou Aurisco Pharmaceutical Co.,Ltd. as recorded, the chemical-drug catalogue lists 2 active records with this name as holder; 12 active API registrations list this name as first registered company.

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference

CDE data as of
2026/11/18
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.

Drug filings

7 acceptance records as first applicant, grouped into 5 source drug names. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Estradiol Tablets 1 records · Latest accepted 2026/08/05

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2601908Generic2026/08/05Yangzhou Aurisco Pharmaceutical Co.,Ltd.CDE ↗
雌二醇片/雌二醇地屈孕酮片复合包装 · No verified English name 3 records · Latest accepted 2026/05/29

Supplement · 1Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2601027Supplement2026/05/29Yangzhou Aurisco Pharmaceutical Co.,Ltd.CDE ↗
CYHS2402081Generic2024/07/09Yangzhou Aurisco Pharmaceutical Co.,Ltd.CDE ↗
CYHS2402080Generic2024/07/09Yangzhou Aurisco Pharmaceutical Co.,Ltd.CDE ↗
Estradiol Valerate Tablets 1 records · Latest accepted 2025/07/09

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2502436Generic2025/07/09Yangzhou Aurisco Pharmaceutical Co.,Ltd.CDE ↗
雌二醇地屈孕酮片 · No verified English name 1 records · Latest accepted 2025/06/18

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2502183Generic2025/06/18Yangzhou Aurisco Pharmaceutical Co.,Ltd.CDE ↗
Dolutegravir Sodium Tablets 1 records · Latest accepted 2024/09/10

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2402993Generic2024/09/10Yangzhou Aurisco Pharmaceutical Co.,Ltd.; Jiangsu He Chen Pharma Co., Ltd. romanizedCDE ↗

Changes in the last 90 days

2 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Marketing application approved: 1 applicationNo longer listed under review: 1 application

  1. 2026/11/18Marketing application approved

    雌二醇地屈孕酮片 · No verified English name

    CYHS2502183 · 国药准字H20266606

    Fact date: 2026/11/18 · Publication date: 2026/11/19 · Date added to this site: 2026/11/19

    View source · Table row 62 ↗
  2. 2026/10/31No longer listed under review

    雌二醇地屈孕酮片 · No verified English name

    CYHS2502183

    Fact date: 2026/10/31 · Date added to this site: 2026/10/31

    Accepted: 2025/06/18

    no longer on the CDE under-review list as of the data cut-off; NMPA published approval-document delivery for this acceptance number on 2026/11/19 (approval no.: 国药准字H20266606; approval date: 2026/11/18) · NMPA source · row 62

    NMPA · Table row 62 ↗ View source ↗

Under review

2 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Estradiol Tablets CYHS2601908Generic2026/08/05Yangzhou Aurisco Pharmaceutical Co.,Ltd.CDE ↗
Estradiol Valerate Tablets CYHS2502436Generic2025/07/09Yangzhou Aurisco Pharmaceutical Co.,Ltd.CDE ↗

Catalogue holder records

2 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
雌二醇片/雌二醇地屈孕酮片复合包装 · No verified English nameYangzhou Aurisco Pharmaceutical Co.,Ltd.Yangzhou Aurisco Pharmaceutical Co.,Ltd.国药准字H202692082026/08/21Generic approved under the new chemical-drug registration classificationCDE ↗
雌二醇片/雌二醇地屈孕酮片复合包装 · No verified English nameYangzhou Aurisco Pharmaceutical Co.,Ltd.Yangzhou Aurisco Pharmaceutical Co.,Ltd.国药准字H202560162025/11/18Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

12 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.

NameCompany / applicantRegistration numberStatusSource update dateView source
雌二醇 · No verified English nameYangzhou Aurisco Pharmaceutical Co.,Ltd.Y20260000482I2026/06/23CDE ↗
硫酸瑞美吉泮 · No verified English nameYangzhou Aurisco Pharmaceutical Co.,Ltd.Y20250000991I2025/09/25CDE ↗
贝派度酸 · No verified English nameYangzhou Aurisco Pharmaceutical Co.,Ltd.Y20250000685I2025/07/29CDE ↗
柯拉特龙 · No verified English nameYangzhou Aurisco Pharmaceutical Co.,Ltd.Y20250000525I2025/05/29CDE ↗
布立西坦 · No verified English nameYangzhou Aurisco Pharmaceutical Co.,Ltd.Y20250000343I2025/05/20CDE ↗
维贝隆 · No verified English nameYangzhou Aurisco Pharmaceutical Co.,Ltd.Y20250000098I2025/02/18CDE ↗
多替拉韦钠 · No verified English nameYangzhou Aurisco Pharmaceutical Co.,Ltd.Y20230001397A2026/05/15CDE ↗
艾拉戈克钠 · No verified English nameYangzhou Aurisco Pharmaceutical Co.,Ltd.Y20230000061I2023/02/16CDE ↗
贝派度酸 · No verified English nameYangzhou Aurisco Pharmaceutical Co.,Ltd.Y20220000562I2022/08/01CDE ↗
布立西坦 · No verified English nameYangzhou Aurisco Pharmaceutical Co.,Ltd.Y20220000479I2022/07/14CDE ↗
尼麦角林 · No verified English nameYangzhou Aurisco Pharmaceutical Co.,Ltd.Y20220000237A2024/03/19CDE ↗
地屈孕酮 · No verified English nameYangzhou Aurisco Pharmaceutical Co.,Ltd.Y20210001253A2023/06/29CDE ↗

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

4 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Dydrogesterone Tablets CYHB2501904Supplement2025/09/25Aurisco Pharmaceutical Co., Ltd.; Yangzhou Aurisco Pharmaceutical Co.,Ltd.CDE ↗
Dydrogesterone Tablets CYHB2401628Supplement2024/10/11Jiangsu He Chen Pharma Co., Ltd. romanized; Yangzhou Aurisco Pharmaceutical Co.,Ltd.CDE ↗
Dydrogesterone Tablets CYHS2201435Generic2022/09/02Hangzhou He Ze Kun Yuan Pharma Co., Ltd. romanized; Yangzhou Aurisco Pharmaceutical Co.,Ltd.CDE ↗
Dydrogesterone Tablets CYHS2102225Generic2021/12/20Aurisco Pharmaceutical Co., Ltd.; Yangzhou Aurisco Pharmaceutical Co.,Ltd.CDE ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/18 · Current coverage may be incomplete
Chemical-drug catalogue
Last successful update: 2026/11/18
API registrations
Last successful update: 2026/11/18
NMPA drug delivery notices
Last successful update: 2026/11/19

Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.